Relepost 20 mg/g barra cutanea

Label: information for the user

Relepost 20 mg/g bar cutaneous strip

Tripelenamine hydrochloride

It contains tripelenamine hydrochloride as its active ingredient, which is an antihistamine, a medication used on the skin to eliminate or reduce the effects of allergies, thereby reducing symptoms such as itching or pain caused by certain agents.

RelePost is used for temporary relief of itching, pain, or stinging due to insect bites or contact with jellyfish or nettles, or mild skin irritation.

Do not use Relepost:

• If you are allergic totripelenamine or related compounds or to any of the other components of this medication (listed in section 6).
• If you have a skin inflammation with liquid secretion and/or small blisters (dermatitis exudativa and/or vesicular).
• In children under 2 years.
• On large skin areasand in case of skin inflammation around the affected area.

Warnings and precautions

Consult your doctor or pharmacistanebefore starting to use RelePost.

Do not use on open wounds

In case ofhaving an allergy to the active ingredient of this medication or the related substance etilendiamina, you may also have cross-sensitivity with antihistamine medications, such as aminofilina or hidroxicina.

Children

This medication should not be used in children under 2 years.

In children over 2 years and under 6, its use should be evaluated, as although absorption is scarce, sedative effects and others may occur.

Other medications and Relepost

Inform your doctor or pharmacist if you are using, have used recently, or may have to use any other medication.

No interactions of this medication are known.

Pregnancy,breastfeeding, and fertility

If you are pregnant or breastfeeding, or think you may be pregnant, consult your pharmacist before using this medication.

Relepost can be used during pregnancy under prescription and during breastfeeding.

No data are available indicating that Relepost affects fertility.

Driving and operating machines

The influence of Relepost on the ability to drive and operate machines is none.

Relepost contains propylene glycol (E1520).

This medication contains 715 mg of propylene glycol in each gram.

Propylene glycol may cause skin irritation.

Follow exactly the medication administration instructions contained in this leaflet or those indicated by your doctor or pharmacist. If in doubt, ask your doctor or pharmacist.

The recommended dose is:

- Adults and children over 6 years of age:

Relepost is applied to the affected skin area. Repeat as needed, up to 3 or 4 times a day.

Cutaneous use.

Slide the bar with a gentle massage on the affected area.

Apply only to small-sized lesions (no larger than the palm of the hand) for short-term treatments (maximum seven days).

Do not use on injured skin (or over wounds).

Use in children

This medication should not be used in children under 2 years of age.

In children over 2 years of age and under 6, the doctor or pharmacist should evaluate its use.

If you use more Relepost than you should

With a topical bar, overdose is not relevant.

In case of systemic overdose, symptoms may include drowsiness, agitation, confusion, tinnitus, blurred vision, dilated pupils, dry mouth, redness, fever, tremors, insomnia, and hallucinations. A toxic reaction has been reported in a child (agitation, convulsions, ...) who used it on a large body surface.

In case of overdose or accidental ingestion, seek immediate medical attention, or consult your doctor or pharmacist, or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.

If you forgot to use Relepost

Do not use a double dose to compensate for the missed doses.

Apply the dose as soon as you remember and the next dose at the usual time.

If you have any other questions about the use of this medication, ask your doctor or pharmacist.

Like all medications, this medication may produce adverse effects, although not all people will experience them.

The most characteristic adverse reaction that can occur is mild irritation and allergic reactions with contact.

Reporting Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is possible adverse effects that do not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.

Keep this medication out of the sight and reach of children.

Store in the original packaging tightly closed. Do not store at a temperature above 25 °C.

Do not refrigerate or freeze.

Do not use this medication after the expiration date that appears on the box and on the base of the topical bar applicatorafter CAD. The expiration date is the last day of the month indicated.

Do not use this medication if you observe a different color than white or a soft product consistency.

Medicines should not be disposed of through drains or in the trash. Dispose of containers and unused medications at thePunto SIGRE of the pharmacy. In case of doubt, ask your pharmacist how to dispose of containers and unused medications. By doing so, you will help protect the environment.

Composition of Relepost

The active ingredient istripelenamine hydrochloride.Each gram contains 20 mg of tripelenamine hydrochloride (2%).

The other components (excipients) are: propylene glycol (E1520), sodium stearate and water.

Appearance of the product and content of the packaging

White, oval-shaped, and consistent skin bar.

Each applicator contains 5.7 grams.

Holder of the marketing authorization and responsible for manufacturing

Holder of the marketing authorization

Perrigo España S.A.

Pza. Xavier Cugat, 2 – Edif. D, Pl. 1ª

08174 Sant Cugat del Vallès (Barcelona), Spain

Responsible for manufacturing

Medgenix Benelux NV

Vliegveld 21

Wevelgem, 8560

Belgium

Last review date of this leaflet:March 2024

The detailed information of this medicine is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/).